论文部分内容阅读
【目的】探讨阿托伐他汀对高脂血症合并颈动脉粥样硬化患者氧化应激因子血清尿酸(UA)、总胆红素(TBIL)、C 反应蛋白(CRP)及同型半胱氨酸(Hcy)水平的影响。【方法】选择2011年1月至2014年12月本院收治的高脂血症合并颈动脉粥样硬化患者135例,根据患者对治疗方案的选择,将其分为对照组58例及阿托伐他汀组77例,对照组仅给予调整饮食和生活方式的治疗方案,阿托伐他汀组则在对照组基础上每晚口服阿托伐他汀钙20 mg。分别在治疗前和治疗后6个月分别检测患者血清 UA、TBIL、CRP 及 Hcy 水平。【结果】经治疗后,两组血清 CRP 水平较治疗前均有显著下降(P =0.047<0.05；P =0.031<0.05)；观察组 Hcy 较治疗有下降(P=0.003<0.05),而 TBIL 水平较治疗前有显著升高(P =0.015<0.05)。治疗后,观察组的血清 Hcy 水平较对照组明显下降(P =0.028<0.05),UA 较对照组显著升高(P =0.035<0.05)。【结论】阿托伐他汀可能通过抗氧化应激机制对高脂血症合并颈动脉粥样硬化起保护作用。“,”Objective]To observe the effects of atorvastatin on the oxidative stress factors like serum uric acid (UA),total bilirubin (TBIL),C reactive protein (CRP)and homocysteine (HCY)in the hyperlipemia patients combined with carotid atherosclerosis.[Methods]135 hyperlipemia patients combined with carotid atherosclerosis in our hospital from 2013 to 2014 were recruited in this study,including 58 patients in the control group and 77 pa-tients in the atorvastatin group.The controls were just given the treatment of diet and living style adjustment.The atorvastatin group was given oral atorvastatin calcium 20mg qn on the basis of the controls.Before and 6 months after treatment,the patients were examined respectively for the serum UA,TBIL,CRP and HCY.[Results]Af-ter treatment,the serum CRP levels of both groups were significantly decreased (P =0.047<0.05;P =0.031<0.05).In the observation group,Hcy was decreased (P =0.003<0.05)compared with that before treatment,and the level of TBIL was significantly higher than that before treatment (P =0.01 5 <0.05);After treatment,the serum Hcy level of the observation group was significantly lower than that of the control group (P = 0.028 <0.05),and UA was significantly higher than that of the control group (P =0.035<0.05).[Conclusion]Atorvasta-tin is likely to protect the hyperlipemia patients combined with carotid atherosclerosis through the mechanism of antioxidant stress.